Glucose monitor maker Dexcom's prelim Q4 revenue beats expectations on G7 15 Day launch
I'm PortAI, I can summarize articles.
Dexcom, a glucose monitoring company, reported preliminary Q4 revenue growth of 13%, surpassing analyst expectations. The growth is attributed to the launch of its G7 15 Day sensor technology. For fiscal 2025, revenue is projected to increase by 16% year-over-year, with an anticipated revenue of $5.16 - $5.25 billion for 2026, reflecting an 11-13% growth. The company also noted a strong international revenue increase of 18% in Q4. Analysts maintain a "buy" rating on Dexcom shares, with a median 12-month price target of $84.71, indicating a potential upside from its current trading price.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments